Depression drug treatment outcomes in pregnancy and the postpartum period: A systematic review and meta-analysis

Obstetrics and Gynecology

Volumn 124, Issue 3, 2014, Pages 526-534

  McDonagh, Marian S ^a   Matthews, Annette ^a   Phillipi, Carrie ^a   Romm, Jillian ^a   Peterson, Kim ^a   Thakurta, Sujata ^a   Guise, Jeanne Marie ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ATTENTION DEFICIT DISORDER; AUTISM; CHILD DEVELOPMENT; CINAHL; COCHRANE LIBRARY; COGNITIVE THERAPY; CONGENITAL MALFORMATION; CONVULSION; DATA EXTRACTION; FUNCTIONAL STATUS; HUMAN; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREGNANCY; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PSYCHOTHERAPY; PUERPERAL DEPRESSION; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY DISTRESS; REVIEW; SCOPUS; SYSTEMATIC REVIEW; BREAST FEEDING; CLASSIFICATION; COMPARATIVE EFFECTIVENESS; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER; FEMALE; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; BREAST FEEDING; COMPARATIVE EFFECTIVENESS RESEARCH; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER; FEMALE; HUMANS; OBSERVATIONAL STUDY AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84925546665     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000410     Document Type: Review

References (75)

1. Grigoriadis S, Vonder Porten EH, Mamisashvili L, Tomlinson G, Dennis C.L., Koren G., et al. The impact of maternal depression during pregnancy on perinatal outcomes: a systematic review and meta-analysis. J Clin Psychiatry 2013; 74: e321-41.
2. Quevedo LA, Silva RA, Godoy R, Jansen K., Matos MB, Tavares Pinheiro KA, et al. The impact of maternal post-partum depression on the language development of children at 12 months. Child Care Health Dev 2012; 38:420-4.
3. Murray L, Cooper PJ Postpartum depression and child development. Psychol Med 1997; 27:253-60.
4. Ludermir AB, Lewis G, Valongueiro S.A., de Araujo TV, Araya R. Violence against women by their intimate partner during pregnancy and postnatal depression: a prospective cohort study. Lancet 2010; 376:903-10.
5. Myers E, Aubuchon-Endsley N, Bastian L., Gierisch J, Kemper A, Swamy G., et al. Efficacy and safety of screening for postpartum depression. Comparative Effectiveness Review No. 106. Rockville (MD): Agency for Healthcare Research and Quality; 2013. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/379/1437/postpartum-screening-report-130409.pdf. Retrieved November 1, 2012.
6. Briggs GG, Freeman RK, Yaffe SJ Drugs in pregnancy and lactation. 7th ed. Philadelphia (PA): Lippincott Williams & Wilkins; 2005.
7. McDonagh M, Matthews A, Phillipi C., Romm J, Peterson K Thakurta S, et al. Antidepressant treatment of depression during pregnancy and the postpartum period. Evidence Report/Technology Assessment No. 216. (Prepared by the Pacific Northwest Evidence-based Practice Center under contract No. 290-2007-10057-I.) AHRQ Publication No. 14-E003-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2014. Available at: www.effectivehealth-care.ahrq.gov/reports/final.cfm. Retrieved July 8, 2014.
8. Methods guide for effectiveness and comparative effectiveness reviews. AHRQ Publication No. 10(14)-EHC063-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2014. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/60/318/CER-Methods-Guide-140109.pdf. Retrieved November 1, 2012.
9. McDonagh MS, Jonas DE, Gartlehner G, Little A., Peterson K, Carson S, et al Methods for the drug effectiveness review project. BMC Med Res Methodol 2012; 12:140.
10. Guyatt GH, Norris SL, Schulman S, Hirsh J., Eckman MH, Akl EA, et al. Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines. Chest 2012; 141 (suppl): 53-70S.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-60.
12. Berkman N, Loh RK, Ansari M, McDonagh M., Balk E, Whitlock E, et al Grading the strength of a body of evidence when assessing health care interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: an update. AHRQ Publication No. 13(14)-EHC130-EF. Rockville (MD): Agency for Healthcare Research and Quality; 2013. Available at: http://www.effectivehealthcare.ahrq.gov/ehc/products/457/1752/methods-guidance-grading-evidence-131118.pdf. Retrieved November 1, 2012.
13. Yonkers KA, Lin H, Howell H.B., Heath AC, Cohen LS. Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. J Clin Psychiatry 2008; 69:659-65.
14. Wisner KL, Hanusa BH, Perel JM Peindl KS, Piontek CM, Sit DK, et al. Postpartum depression: a randomized trial of sertraline versus nortriptyline. J Clin Psychopharmacol 2006; 26:353-60.
15. Bloch M, Meiboom H, Lorberblatt M., Bluvstein I, Aharonov I, Schreiber S. The effect of sertraline add-on to brief dynamic psychotherapy for the treatment of postpartum depression: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012; 73:235-41.
16. Appleby L, Warner R Whitton A, Faragher B. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ 1997; 314:932-6.
17. Sharp DJ, Chew-Graham C, Tylee A., Lewis G, Howard L, Anderson I., et al. A pragmatic randomised controlled trial to compare antidepressants with a community-based psychosocial intervention for the treatment of women with postnatal depression: the RESPOND trial. Health Technol Assess 2010; 14:iii-iv, ix-xi, 1-153.
18. Misri S, Reebye P, Corral M., Milis L The use of paroxetine and cognitive-behavioral therapy in postpartum depression and anxiety: a randomized controlled trial. J Clin Psychiatry 2004; 65:1236-41.
19. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A., Gaylor E, DeBattista A, et al Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142:402-8.
20. Suri R Altshuler L, Hendrick V, Rasgon N, Lee E, Mintz J. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004; 7:193-200.
21. Wisner KL, Sit DK, Hanusa B.H., Moses-Kolko EL, Bogen DL, Hunker D.F., et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557-66.
22. Yonkers KA, Norwitz ER Smith MV, Lockwood CJ, Gotman N, Luchansky E, et al. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology 2012; 23:677-85.
23. Wisner KL, Bogen DL, Sit D, McShea M., Hughes C, Rizzo D, et al Does fetal exposure to SSRIs or maternal depression impact infant growth? Am J Psychiatry 2013; 170:485-93.
24. Pearlstein TB, Zlotnick C, Battle C.L., Stuart S., O'Hara MW, Price AB, et al Patient choice of treatment for postpartum depression: a pilot study. Arch Womens Ment Health 2006; 9: 303-8.
25. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010; 125:e600-8.
26. Oberlander TF, Warburton W, Misri S., Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63:898-906.
27. Suri R Hellemann G, Stowe ZN, Cohen LS, Aquino A, Altshuler LL. A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J Clin Psychiatry 2011; 72:1002-7.
28. Sit D, Perel JM, Wisniewski SR Helsel JC, Luther JF, Wisner KL. Mother-infant antidepressant concentrations, maternal depression, and perinatal events. J Clin Psychiatry 2011; 72:994-1001.
29. Berle JO, Steen VM, Aamo T.O., Breilid H., Zahlsen K, Spigset O. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004; 65:1228-34.
30. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192:932-6.
31. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21:157-71.
32. Nulman I, Rovet J, Stewart D.E., Wolpin J., Pace-Asciak P, Shuhaiber S, et al Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159:1889-95.
33. Nulman I, Koren G, Rovet J., Barrera M, Pulver A, Streiner D., et al. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am J Psychiatry 2012; 169: 1165-74.
34. Pawluski JL, Galea LA, Brain U, Papsdorf M., Oberlander TF. Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors. Pediatrics 2009; 124: e662-70.
35. Palmsten K, Setoguchi S, Margulis A.V., Patrick AR Hernández-Diaz S. Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants? Am J Epidemiol 2012; 175:988-97.
36. Oberlander TF, Papsdorf M, Brain U.M., Misri S., Ross C, Grunau RE. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch Pediatr Adolesc Med 2010; 164:444-51.
37. Logsdon MC, Wisner K, Sit D., Luther JF, Wisniewski SR Depression treatment and maternal functioning. Depress Anxiety 2011; 28:1020-6.
38. Bogen DL, Hanusa BH, Moses-Kolko E, Wisner KL. Are maternal depression or symptom severity associated with breastfeeding intention or outcomes? J Clin Psychiatry 2010; 71: 1069-78.
39. Chambers CD, Johnson KA, Dick L.M., Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010-5.
40. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158:312-6.
41. Davis RL, Rubanowice D, McPhillips H., Raebel MA, Andrade SE, Smith D, et al Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007; 16:1086-94.
42. Ferreira E, Carceller AM, Agogue C, Martin B.Z., St-André M, Francoeur D, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007; 119:52-9.
43. Grzeskowiak LE, Gilbert AL, Morrison JL Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors. J Clin Psychopharmacol 2012; 32:615-21.
44. Latendresse G, Ruiz RJ Maternal corticotropin-releasing hormone and the use of selective serotonin reuptake inhibitors independently predict the occurrence of preterm birth. J Midwifery Womens Health 2011; 56:118-26.
45. Lennestal R Källén B. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J Clin Psychopharmacol 2007; 27:607-13.
46. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A., Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012; 32:186-94.
47. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40:1723-33.
48. Wen SW, Yang Q, Garner P., Fraser W, Olatunbosun O, Nimrod C., et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194:961-6.
49. Sivojelezova A, Shuhaiber S, Sarkissian L., Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am J Obstet Gynecol 2005; 193:2004-9.
50. Colvin L, Slack-Smith L, Stanley F.J., Bower C. Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in Western Australia. CNS Drugs 2012; 26:el-14.
51. Jordan AE, Jackson GL, Deardorff D, Shivakumar G., Mclntire DD, Dashe JS. Serotonin reuptake inhibitor use in pregnancy and the neonatal behavioral syndrome. J Matern Fetal Neonatal Med 2008; 21:745-51.
52. Jimenez-Solem E., Andersen JT, Petersen M, Broedbaek K Lander AR Afzal S, et al. SSRI use during pregnancy and risk of stillbirth and neonatal mortality. Am J Psychiatry 2013; 170: 299-304.
53. Stephansson O, Keler H, Haglund B., Artama M, Engeland A, Furu K et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMÄ 2013; 309:48-54.
54. Colvin L, Slack-Smith L, Stanley F.J., Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011; 91:142-52.
55. Davidson S, Prokonov D, Taler M., Maayan R Harell D, Gil-Ad I, et al. Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res 2009; 65:236-41.
56. Jimenez-Solem E., Andersen JT, Petersen M, Broedbaek K Jensen JK Afzal S, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012; 2. pii: e001148.
57. Källén BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007; 79:301-8.
58. Kornum JB, Nielsen RB, Pedersen L, Mortensen P.B., Nørgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010; 2:29-36.
59. Kulin NA Pastuszak A, Sage SR Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-10.
60. Laine K, Heikkinen T, Ekblad U., Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60:720-6.
61. Malm H, Artama M, Gissler M., Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118:111-20.
62. Oberlander TF, Bonaguro RJ, Misri S, Papsdorf M., Ross CJ, Simpson EM. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008; 13:65-73.
63. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J., Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009; 339:b3569.
64. Simon GE, Cunningham ML, Davis RL Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055-61.
65. Rampono J, Simmer K Ilett KF, Hackett LP, Doherty DA, Elliot R et al. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 2009; 42: 95-100.
66. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579-87.
67. Keler H, Artama M, Engeland A., Ericsson O, Furu K Gissler M, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344:d8012.
68. Figueroa R. Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. J Dev Behav Pediatr 2010; 31:641-8.
69. Croen LA, Grether JK Yoshida CK, Odouli R Hendrick V. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011; 68: 1104-12.
70. Rai D, Lee BK Dalman C, Golding J, Lewis G, Magnusson C. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 2013; 346:f2059.
71. Lanza di Scalea T, Hanusa BH, Wisner KL. Sexual function in postpartum women treated for depression: results from a randomized trial of nortriptyline versus sertraline. J Clin Psychiatry 2009; 70:423-8.
72. Yonkers KA, Wisner KL, Stewart D.E., Oberlander TF, Dell DL, Stotland N, et al The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009; 31:403-13.
73. Hale TW. Medication and mother's milk 2012: a manual of lactational pharmacology. 15th ed. Amarillo (TX): Hale Publishing LP; 2012.
74. Ross LE, Grigoriadis S, Mamisashvili L., Vonderporten EH, Roerecke M, Rehm J, et al Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 2013; 70: 436-43.
75. Yonkers KA, Blackwell KA, Glover J, Forray A. Antidepressant use in pregnant and postpartum women. Annu Rev Clin Psychol 2014; 10:369-92.